Boston Scientific has settled three patent disputes with Johnson & Johnson (J&J) for $1.73 billion.
The Taxcor Plus, a paclitaxel-eluting coronary stent system, has received a CE mark of approval for device distribution.
David E. Gossman, MD, an interventional cardiologist, who until his termination in September performed cardiac catheterizations and other cardiac interventional procedures at the Lahey Clinic Medical Center and Lahey Clinic Hospital in Burlington, Mass., is accusing his former employer of terminating him due to his refusal to increase the use of Medtronic products.
Abbott has increased its net sales and net earnings for the third quarter of 2009, which ended Sept. 30, bolstered by strong vascular sales in both the international and U.S. markets.
Boston Scientific has reported positive financial earnings for its fiscal 2009 second quarter, which ended June 30. The Natick, Mass.-based medical device company booked a net income of $158 million this quarter, compared with $98 million in the second quarter of 2008.
Boston Scientific has received FDA approval to market its Taxus Liberte Long paclitaxel-eluting coronary stent system, a drug-eluting stent (DES) designed for long lesions.
Coronary stent developer Stentys has secured the second tranche of its Series B financing from Sofinnova Partners and Scottish Equity Partners -- closing an additional $4.2 million investment from new investor Crédit Agricole Private Equity -- bringing the total B round financing to more than $22 million.
|
To add to the ongoing drama circulating around the St. Joseph Medical Center in Towson, Md., last week Maryland attorneys filed a class action lawsuit against the facility after 369 patients received notifications saying that they may have received unwarranted cardiac stents.
Cardiologists and cardiovascular staff at Sanford USD Medical Center in Sioux Falls, S.D., pride themselves for providing the best care in the area. But it took the process associated with gaining Chest Pain Center accreditation for them to realize just how good they are.
With the exception of evaluation and management services, nearly all services that cardiologists perform will see cuts ranging from 10 percent to more than 40 percent for individual services phased in over four years, according to the just-released Centers for Medicare and Medicaid Services (CMS) 2010 Medicare Physician Fee Schedule final rule. The cuts will be phased in over a four-year period, which is a slight change from the proposed rule.
SAN FRANCISCO—Abbott’s Xience V stent demonstrates enhanced safety and efficacy compared with Boston Scientific’s Taxus Express without routine angiographic follow-up, according to the one-year clinical data of SPIRIT IV presented at the late-breaking clinical trials session on Wednesday at the Transcatheter Cardiovascular Therapeutics conference. However, both stents produced positive clinical outcomes.
Abbott today settled all outstanding intellectual property litigation with Medtronic. Under the terms of the settlement, Medtronic will pay Abbott $400 million and $42 million to evYsio Medical Devices, based in Vancouver, British Columbia.
Abbott posted its financial results for the second quarter, which ended June 30, showing a 2.6 percent decrease in net earnings--to $1.29 billion from $1.32 billion in the same period last year.
Abbott has received CE Mark for its next-generation Xience Prime everolimus-eluting coronary stent system for the treatment of coronary artery disease. The company plans to launch Xience Prime in a varied size matrix, with lengths up to 38 mm, in the third quarter across Europe.
|
RSS 
Middle age introduces itself in many ways; one is atrial fibrillation (AF). My onset of AF seems to have coincided with a mountain bike accident in the woods of North Carolina that resulted in some cracked ribs.
The use of health IT to reduce rehospitalizations will be welcome but also disruptive, said Stephen Jencks, an independent consultant in healthcare safety during a Feb. 24 webinar on the potential use of health IT to mitigate rehospitalizations, sponsored by the Agency for Healthcare Research and Quality (AHRQ).